BioLeap The Intellectual Property Engine for Drug Discovery

 

 

 

 

 

 

 

News:

  • February 2009:  BioLeap appoints David L. Pompliano, PhD as CEO  RELEASE
  • February 2009:  BioLeap strengthens Board of Directors:  Appoints Andrew Powell, Esq. RELEASE

 Senior Management

Board of Advisers

• Contact

 

 

About BioLeap:

BioLeap is a drug discovery company driven by proprietary, next generation computational fragment-based drug design technology. Our platform provides BioLeap's drug designers with the information and tools to rapidly create new chemical entities, molecularly tailored to treat a particular disease process.

BioLeap changes the paradigm for identifying chemical starting points and for deciding which compounds to make next during lead optimization, obviating the need for costly high throughput screening or synthetic chemical tinkering.

Shared Risk Collaborations:

BioLeap is interested in shared risk opportunities where conventional industry approaches have been unsuccessful in progressing drug discovery efforts on compelling targets.  We design and delivery novel, active compounds at the lead identification or development candidate stages of drug development.

Please contact us to discuss our capabilities, successes and your needs:

Technology Overview